C12Y 603/04005
Argininosuccinate synthase
Official title: Argininosuccinate synthase (6.3.4.5)
C12Y603/04005 (Argininosuccinate synthase) appears on 11 US grants and 30 published applications in this corpus.
Search patents in C12Y- Granted patents
- 11
- Published applications
- 30
- Assignees
- 16
- Inventors
- 56
- Latest grant
- 10 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 1 | 2 |
| 2018 | 0 | 1 |
| 2019 | 0 | 1 |
| 2020 | 1 | 2 |
| 2021 | 0 | 2 |
| 2022 | 3 | 1 |
| 2023 | 0 | 4 |
| 2024 | 2 | 4 |
| 2025 | 1 | 4 |
| 2026 | 2 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Modulation of protein degradation10 Feb 2026US 12,546,776 B2Orionis Biosciences BV
- MRNA therapy for argininosuccinate synthetase deficiency27 Jan 2026US 12,533,402 B2Translate Bio, Inc.
- Gene therapy for treating citrullenemia12 Aug 2025US 12,385,065 B2The Trustees of the University of Pennsylvania
- Method for the fermentative production of guanidinoacetic acid20 Aug 2024US 12,065,677 B2Evonik Operations GmbH
- Processes of preparing mRNA-loaded lipid nanoparticles30 Apr 2024US 11,969,480 B2Translate Bio, Inc.
- Method for the fermentative production of guanidinoacetic acid using a microorganism comprising a heterologous l-threonine 3-dehydrogenase gene (tdh) and a glycine c-acetyltransferase gene (kbl)6 Aug 2026US 2026/0226404 A1Evonik Operations GmbH
- Fermentative production guanidinoacetic acid (gaa) from serine by attenuating l serine ammonia lyase activity in microorganisms30 Jul 2026US 2026/0218253 A1Evonik Operations GmbH
- Methods and Compositions for the Adar-Mediated Editing of Argininosuccinate Synthetase (ASS1)16 Jul 2026US 2026/0201388 A1Korro Bio, Inc.
- Modulation of protein degradation14 May 2026US 2026/0133195 A1Orionis Biosciences BV
- Gene therapy for treating citrullenemia19 Mar 2026US 2026/0078405 A1The Trustees of the University of Pennsylvania
Most cited
By later US patents
- MRNA therapy for argininosuccinate synthetase deficiency4US 11,224,642 B2Translate Bio, Inc. · 2022
- Gene therapy for treating citrullenemia3US 11,535,866 B2The Trustees of the University of Pennsylvania · 2022
- Polynucleotides targeted against the extended 5′-UTR region of argininosuccinate synthase and uses thereof3US 7,718,625 B2University of South Florida · 2010
- Method for the fermentative production of guanidinoacetic acid1US 12,065,677 B2Evonik Operations GmbH · 2024